NeuroMatch Access dashboard display. Image credit: LVIS.

LVIS Corporation has launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US.

The Silicon Valley, US-based company’s platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

EEG is used to measure electrical activity of the brain and can aid in the diagnosis of conditions including brain damage and epilepsy.

NeuroMatch Access is intended to speed-up and improve the efficiency of clinical workflows by providing real-time visualisations of brain circuits to support diagnosis and the planning of targeted care strategies for brain conditions.

“NeuroMatch represents a transformative step towards democratising neurological care for patients worldwide,” said LVIS founder Dr Jin Hyung Lee.

“Our commitment is to harness advanced technology to not only expedite EEG diagnostics but also to make these critical services accessible to all.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier this year, LVIS rolled NeuroMatch out in 10 hospitals across  South Korea, with the company also launching its first NeuroMatch Center, an educational hub located in the South Korean city of Daegu, in June 2024. The hub features monitoring rooms for EEG diagnostics and a lecture hall for training healthcare professionals.

According to GlobalData analysis, the global electrical activity testing segment of the neurology devices market was valued at around $1.29bn in 2023 and is forecast to reach a valuation of around $1.52bn by 2033.

A 2023 Market Model methodology by GlobalData found that Nihon Kohden was the biggest player in the $200m US electrical activity testing market, followed by Natus Medical and Medtronic.

Elsewhere in EEG, Natus sought FDA clearance for its point-of-care EEG device in October 2024, while Zeto gained FDA clearance for Zeto ONE, an EEG headset and workflow management platform, in June.